calaa-01
Nucleic acidexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2008 (NCT00689065)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Ribonucleotide reductaseANTISENSE INHIBITOR
Ribonucleotide reductase antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- calaa-01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00689065 | Phase 1 | May 1, 2008 | Calando Pharmaceuticals, City of Hope National Medical Center, South Texas Accelerated Research Therapeutics, University of California, Los Angeles |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Calando Pharmaceuticals | For profit | 1 | 1 | 1 | 2008 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2008 |
| South Texas Accelerated Research Therapeutics | For profit | 1 | 0 | 1 | 2008 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1